Global Smoking Cessation Drugs Market Forecast 2017-2027

LONDON, November 8, 2017 /PRNewswire/ --

NRT, Non-nicotine Pharmacotherapy, Prescription Drugs, OTC Drugs

The global smoking cessation drugs market is expected to grow at a CAGR of 14.9% in the first half of the forecast period. In 2016, the non-nicotine pharmacotherapy submarket held 56.2% of the global smoking cessation drugs market.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you: 

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 280-page report you will receive 175 tables and 150 figures- all unavailable elsewhere.

The 280-page report provides clear detailed insight into the global smoking cessation drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope 

• Global Smoking Cessation Drugs market forecasts from 2017-2027

• This report also breaks down the revenue forecast for the global smoking cessation drugs market by type of therapy:
- NRT
- Non-Nicotine Pharmacotherapy

• This report also breaks down the revenue forecast for the global smoking cessation drugs market by prescription vs OTC:
- Prescription drugs
- OTC

• This report provides individual revenue forecasts to 2027 for these regions:
- North America
- Europe
- Asia-Pacific
- RoW

Each region is further segmented by type of therapy. 

• This report provides the following qualitative analysis:
- Epidemiology by geography, available treatment options, along with humanistic and economic burden
- A SWOT Analysis
- Pipeline molecules which are under development for the treatment of smoking cessation and detailed analysis on promising drug candidates
- Pricing and reimbursement overview of the smoking cessation drugs market.
- Leading companies that are the major players in the global smoking cessation drugs industry, including Pfizer, GlaxoSmithKline and Johnson & Johnson.

Visiongain's study is intended for anyone requiring commercial analyses for the global smoking cessation drugs market. You find data, trends and predictions.

Buy our report today Global Smoking Cessation Drugs Market Forecast 2017-2027: NRT, Non-nicotine Pharmacotherapy, Prescription Drugs, OTC Drugs.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or +44-(0)-20-7336-6100 or refer to our website: https://www.visiongain.com/Report/2042/Global-Smoking-Cessation-Drugs-Market-Forecast-2017-2027

List of Companies and Organizations Mentioned in the Report 

22nd Century Group, Inc

Actavis (Teva)

AFT Pharmaceuticals

Alphapharm

Apotex

Aveva

Celtic Pharmaceuticals (earlier Xenova Group)

Cerecor Inc

Chefaro Pharma

Chrono Therapeutics

CV Sciences

Douglas Pharmaceuticals

Dr Reddys Labs

Eisai/Arena Pharmaceuticals

Embera NeuroTherapeutics

FDA

Forum Pharmaceuticals Mitsubishi Tanabe Pharma

Geiss, Destin & Dunn (GDD) Inc.

Gelmedic Holding

GSK

GSKSS

Ivax Sub Teva Pharms

Kern Pharma

McNeil (J&J)

Medis Pharma

Merck

Mylan

Nabi Pharmaceuticals (now Aviragen)/GSK

National Institute on Drug Abuse

Novartis

Novartis/Cytos Biotechnology (now Kuros BioSciences)

Office on Smoking and Health

Omega Pharma

Orion Laboratories (Perrigo)

Perrigo

Pfizer

Pharmacia and Upjohn (Pfizer)

Pharmacia Italia

Pierre Fabre

Pinney Associates

Recordati Chimica Industria E Farmaceutica

Reynolds America

Sanofi

Sanofi Aventis

Selecta Biosciences

Tarbis Farma

Teva

The Boots Company

University of Washington

Watson Labs (Teva)

WHO

Wrafton Laboratories (Perrigo)

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com